176 related articles for article (PubMed ID: 32621022)
1. Serum levels of the IL-6 family of cytokines predict prognosis in renal cell carcinoma (RCC).
Gudbrandsdottir G; Aarstad HH; Bostad L; Hjelle KM; Aarstad HJ; Bruserud Ø; Tvedt THA; Beisland C
Cancer Immunol Immunother; 2021 Jan; 70(1):19-30. PubMed ID: 32621022
[TBL] [Abstract][Full Text] [Related]
2. The levels of IL-6 and soluble IL-33R are increased in the renal vein during surgery for clear cell renal cell carcinoma.
Gudbrandsdottir G; Aarstad HH; Hjelle KM; Førde K; Reisæter L; Bostad L; Aarstad HJ; Beisland C
Cytokine; 2021 Aug; 144():155586. PubMed ID: 34058568
[TBL] [Abstract][Full Text] [Related]
3. Preoperative high levels of serum vascular endothelial growth factor are a prognostic marker for poor outcome after surgical treatment of renal cell carcinoma.
Guðbrandsdottir G; Hjelle KM; Frugård J; Bostad L; Aarstad HJ; Beisland C
Scand J Urol; 2015; 49(5):388-94. PubMed ID: 25773545
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of interleukin-6 in renal cell carcinoma: a meta-analysis.
Wang Y; Zhang Y
Clin Transl Oncol; 2020 Jun; 22(6):835-843. PubMed ID: 31410730
[TBL] [Abstract][Full Text] [Related]
5. MCP-1/MCPIP-1 Signaling Modulates the Effects of IL-1β in Renal Cell Carcinoma through ER Stress-Mediated Apoptosis.
Lee CH; Hung PF; Lu SC; Chung HL; Chiang SL; Wu CT; Chou WC; Sun CY
Int J Mol Sci; 2019 Dec; 20(23):. PubMed ID: 31816951
[TBL] [Abstract][Full Text] [Related]
6. Resistin and interleukin 6 as predictive factors for recurrence and long-term prognosis in renal cell cancer.
Kallio J; Hämäläinen M; Luukkaala T; Moilanen E; Tammela TL; Kellokumpu-Lehtinen PL
Urol Oncol; 2017 Sep; 35(9):544.e25-544.e31. PubMed ID: 28572026
[TBL] [Abstract][Full Text] [Related]
7. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma.
Polimeno M; Napolitano M; Costantini S; Portella L; Esposito A; Capone F; Guerriero E; Trotta A; Zanotta S; Pucci L; Longo N; Perdonà S; Pignata S; Castello G; Scala S
BJU Int; 2013 Sep; 112(5):686-96. PubMed ID: 23495770
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie.
Negrier S; Perol D; Menetrier-Caux C; Escudier B; Pallardy M; Ravaud A; Douillard JY; Chevreau C; Lasset C; Blay JY;
J Clin Oncol; 2004 Jun; 22(12):2371-8. PubMed ID: 15197198
[TBL] [Abstract][Full Text] [Related]
9. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
[TBL] [Abstract][Full Text] [Related]
10. Tumour necrosis factor-alpha, interleukin-1 beta and interleukin-6 in patients with renal cell carcinoma.
Dosquet C; Schaetz A; Faucher C; Lepage E; Wautier JL; Richard F; Cabane J
Eur J Cancer; 1994; 30A(2):162-7. PubMed ID: 8155390
[TBL] [Abstract][Full Text] [Related]
11. [Role of serum E-selectin (ELAM-1) and inflammatory parameters in patients with renal cell carcinoma].
Muraki J; Kobayashi M; Sugaya Y; Hashimoto S; Morita T; Kobayashi Y; Tokue A
Nihon Hinyokika Gakkai Zasshi; 1996 May; 87(5):831-41. PubMed ID: 8691708
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 6 induces cell proliferation of clear cell renal cell carcinoma by suppressing hepaCAM via the STAT3-dependent up-regulation of DNMT1 or DNMT3b.
Quan Z; He Y; Luo C; Xia Y; Zhao Y; Liu N; Wu X
Cell Signal; 2017 Apr; 32():48-58. PubMed ID: 28093267
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.
Klatte T; Seligson DB; Riggs SB; Leppert JT; Berkman MK; Kleid MD; Yu H; Kabbinavar FF; Pantuck AJ; Belldegrun AS
Clin Cancer Res; 2007 Dec; 13(24):7388-93. PubMed ID: 18094421
[TBL] [Abstract][Full Text] [Related]
14. High YKL-40 is associated with poor survival in patients with renal cell carcinoma: a novel independent prognostic marker.
Väänänen T; Kallio J; Vuolteenaho K; Ojala A; Luukkaala T; Hämäläinen M; Tammela T; Kellokumpu-Lehtinen PL; Moilanen E
Scand J Urol; 2017 Oct; 51(5):367-372. PubMed ID: 28644702
[TBL] [Abstract][Full Text] [Related]
15. [Predicting postoperative recurrence of renal cell carcinoma using serum vascular endothelial growth factor].
Fujita N; Okegawa T; Tambo M; Shishido T; Nutahara K; Higashihara E
Nihon Hinyokika Gakkai Zasshi; 2013 Jan; 104(1):1-5. PubMed ID: 23457926
[TBL] [Abstract][Full Text] [Related]
16. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of interleukin-18 and nitrite+nitrate in renal cell carcinoma patients with different tumor stage and grade.
Sözen S; Coskun U; Sancak B; Bukan N; Günel N; Tunc L; Bozkirli I
Neoplasma; 2004; 51(1):25-9. PubMed ID: 15004655
[TBL] [Abstract][Full Text] [Related]
18. Myeloid-derived suppressor cell accumulation in renal cell carcinoma is correlated with CCL2, IL-17 and IL-18 expression in blood and tumors.
Guan X; Liu Z; Zhang J; Jin X
Adv Clin Exp Med; 2018 Jul; 27(7):947-953. PubMed ID: 29905412
[TBL] [Abstract][Full Text] [Related]
19. [Significance of plasma interleukin-6 in the diagnosis of renal cell carcinoma].
Kamemoto H
Hinyokika Kiyo; 1993 Apr; 39(4):301-6. PubMed ID: 8503325
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-33 Predicts Poor Prognosis and Promotes Renal Cell Carcinoma Cell Growth Through its Receptor ST2 and the JNK Signaling Pathway.
Wu CW; Wu YG; Cheng C; Hong ZD; Shi ZM; Lin SQ; Li J; He XY; Zhu AY
Cell Physiol Biochem; 2018; 47(1):191-200. PubMed ID: 29763892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
